Valeant pays $65M upfront for U.S. rights to Eisai's Targretin

02/22/2013 | Genetic Engineering & Biotechnology News

Eisai has sold the U.S. rights to Targretin capsules and 1% gel to Valeant Pharmaceuticals for $65 million plus possible milestone fees. Valeant will handle the new drug application and other regulatory obligations in the U.S. Targretin, or bexarotene, capsules and gel are used to treat patients with skin problems associated with cutaneous T-cell lymphoma who failed to respond to at least one systemic treatment.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA